Literature DB >> 9166841

In vitro development of erythroid and megakaryocytic cells from a UT-7 subline, UT-7/GM.

N Komatsu1, K Kirito, R Shimizu, M Kunitama, M Yamada, M Uchida, M Takatoku, M Eguchi, Y Miura.   

Abstract

UT-7 is a human megakaryoblastic leukemia cell line with absolute dependence on interleukin-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), or erythropoietin (EPO) for growth and survival. We isolated a novel subline, UT-7/GM after long-term culture of UT-7 with GM-CSF. The hemoglobin concentration and gamma-globin and EPO-receptor mRNA levels were significantly higher in EPO-treated UT-7/GM cells than in untreated cells. In contrast, the platelet factor 4 and glycoprotein IIb mRNA levels were much higher in thrombopoietin (TPO)-treated UT-7/GM cells than in untreated cells. Some TPO-treated cells had morphologically mature megakaryocytic characteristics such as a developed demarcation membrane in the cytoplasm and multilobular nuclei. These findings indicate that UT-7/GM is a bipotential cell line that can be induced to differentiate into erythroid and megakaryocytic lineages by EPO and TPO, respectively. Moreover, a minority of UT-7/GM cells acquired a high hemoglobin concentration by treatment with TPO, suggesting that TPO in part induced the erythroid differentiation of the UT-7/GM cells. Interestingly, GM-CSF inhibited the EPO- or TPO-induced erythroid differentiation and the TPO-induced megakaryocytic differentiation of UT-7/GM cells. These results support the hypothesis that cytokines influence the programming of gene expression required for lineage commitment or differentiation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9166841

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Platelets and platelet-like particles mediate intercellular RNA transfer.

Authors:  Antonina Risitano; Lea M Beaulieu; Olga Vitseva; Jane E Freedman
Journal:  Blood       Date:  2012-05-17       Impact factor: 22.113

2.  A functional role of mitogen-activated protein kinases, erk1 and erk2, in the differentiation of a human leukemia cell line, UT-7/GM: a possible key factor for cell fate determination toward erythroid and megakaryocytic lineages.

Authors:  M Uchida; K Kirito; R Shimizu; Y Miura; K Ozawa; N Komatsu
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

3.  Robust hematopoietic progenitor cell commitment in the presence of a conflicting cue.

Authors:  Najaf A Shah; Marshall J Levesque; Arjun Raj; Casim A Sarkar
Journal:  J Cell Sci       Date:  2015-07-09       Impact factor: 5.285

4.  Relationships between DNA methylation and expression in erythrocyte membrane protein (band 3, protein 4.2, and beta-spectrin) genes during human erythroid development and differentiation.

Authors:  Ralph Remus; Akio Kanzaki; Ayumi Yawata; Hideho Wada; Hidekazu Nakanishi; Takashi Sugihara; Michael Zeschnigk; Ines Zuther; Birgit Schmitz; Frauke Naumann; Walter Doerfler; Yoshihito Yawata
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

5.  CD36 and TLR interactions in inflammation and phagocytosis: implications for malaria.

Authors:  Laura K Erdman; Gabriela Cosio; Andrew J Helmers; D Channe Gowda; Sergio Grinstein; Kevin C Kain
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422

6.  Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling.

Authors:  Pardeep Heir; Tharan Srikumar; George Bikopoulos; Severa Bunda; Betty P Poon; Jeffrey E Lee; Brian Raught; Michael Ohh
Journal:  J Biol Chem       Date:  2016-02-04       Impact factor: 5.157

7.  A common signaling pathway is activated in erythroid cells expressing high levels of fetal hemoglobin: a potential role for cAMP-elevating agents in β-globin disorders.

Authors:  Tohru Ikuta; Yuichi Kuroyanagi; Nadine Odo; Siyang Liu
Journal:  J Blood Med       Date:  2013-12-04

8.  Identification of AIM2 as a downstream target of JAK2V617F.

Authors:  Ei Leen Liew; Marito Araki; Yumi Hironaka; Seiichi Mori; Tuan Zea Tan; Soji Morishita; Yoko Edahiro; Akimichi Ohsaka; Norio Komatsu
Journal:  Exp Hematol Oncol       Date:  2016-01-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.